2017
DOI: 10.1007/s12031-017-0983-0
|View full text |Cite
|
Sign up to set email alerts
|

Tau Diagnostics and Clinical Studies

Abstract: This short editorial provides our point of view of the first EURO TAU meeting focusing on tau diagnostics and clinical studies. We cover postmortem analyses toward the identification of new biomarkers, tau imaging as a diagnostic biomarker, cerebrospinal fluid (CSF) sampling with emphasis on tau fragments, blood tests and genetic evaluations for sporadic cases, treatment aspects, drug development and points for future developments toward disease modification of devastating tauopathies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
1
1

Relationship

2
6

Authors

Journals

citations
Cited by 11 publications
(3 citation statements)
references
References 90 publications
0
3
0
Order By: Relevance
“…Our studies explain, in part, the efficacy of NAP (davuntide, CP201) in enhancing cognitive functions in mild cognitive impairment patients (18), while showing no efficacy (although high safety) in the 4R tauopathy progressive supranuclear palsy (PSP) (19). Since tauopathy underlies a verity of neurodegenerative conditions, our current findings may pave the path for treatment by peptide drugs that have an impact on tubulin-Tau interaction and specific neurofibrillary tangle populations (50). As neurodevelopment has been linked to Tau3R (7, 10), our results pave the path to the development of NAP (davunetide, CP201) for ADNP deficiencies associated with neurodevelopment, for example, the autism-like ADNP syndrome, resulting from de novo truncating mutations in ADNP (32).…”
Section: Discussionmentioning
confidence: 90%
“…Our studies explain, in part, the efficacy of NAP (davuntide, CP201) in enhancing cognitive functions in mild cognitive impairment patients (18), while showing no efficacy (although high safety) in the 4R tauopathy progressive supranuclear palsy (PSP) (19). Since tauopathy underlies a verity of neurodegenerative conditions, our current findings may pave the path for treatment by peptide drugs that have an impact on tubulin-Tau interaction and specific neurofibrillary tangle populations (50). As neurodevelopment has been linked to Tau3R (7, 10), our results pave the path to the development of NAP (davunetide, CP201) for ADNP deficiencies associated with neurodevelopment, for example, the autism-like ADNP syndrome, resulting from de novo truncating mutations in ADNP (32).…”
Section: Discussionmentioning
confidence: 90%
“…Our studies explain, in part, the efficacy of NAP (davuntide, CP201) in enhancing cognitive functions in mild cognitive impairment patients [18], while showing no efficacy (although high safety) in the 4R tauopathy progressive supranuclear palsy (PSP) [19]. Since tauopathy underlies a verity of neurodegenerative conditions, our current findings may pave the path for treatment by peptide drugs that have an impact on tubulin-Tau interaction and specific neurofibrillary tangle populations [51]. As neurodevelopment has been linked to Tau3R [7, 10], our results pave the path to the development of NAP (davunetide, CP201) for ADNP deficiencies associated with neurodevelopment, for example, the autism-like ADNP syndrome, resulting from de novo truncating mutations in ADNP (32).…”
Section: Discussionmentioning
confidence: 97%
“…AD involves a set of varying cognitive, functional, and behavioral dysfunctions resulting from neuropathological and biochemical changes in patients’ brains and may culminate in dramatic loss of autonomy (Schott & Warren, 2012). Its diagnosis is eminently clinical and entails a gradual and progressive neurodegenerative decline being translated into worse performance in cognitive tasks over time (Gozes, Höglinger, Quinn, Hooper, & Höglund, 2017). By and large, a progressive loss of memory is observed in AD; for recent events initially, as well as substantial difficulties in learning and decision making (Bondi, Edmonds, & Salmon, 2017).…”
Section: Dementia and Alzheimer’s Diseasementioning
confidence: 99%